0001013762-23-005659.txt : 20231023 0001013762-23-005659.hdr.sgml : 20231023 20231023111250 ACCESSION NUMBER: 0001013762-23-005659 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231023 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231023 DATE AS OF CHANGE: 20231023 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Unicycive Therapeutics, Inc. CENTRAL INDEX KEY: 0001766140 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813638692 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40582 FILM NUMBER: 231339072 BUSINESS ADDRESS: STREET 1: 4300 EL CAMINO REAL, SUITE 210 CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 650-384-0642 MAIL ADDRESS: STREET 1: 4300 EL CAMINO REAL, SUITE 210 CITY: LOS ALTOS STATE: CA ZIP: 94022 8-K 1 ea187125-8k_unicycive.htm CURRENT REPORT
0001766140 false 0001766140 2023-10-23 2023-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 23, 2023

 

Unicycive Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

   001-40582   81-3638692
(State or other jurisdiction of
incorporation or organization)		   (Commission File Number)   IRS Employer
Identification No.)

 

4300 El Camino Real, Suite 210

Los Alto, CA 94022

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (650) 351-4495

 

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:
Common Stock   UNCY   Nasdaq Capital Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 8.01 Other Events.

 

On October 23, 2023, Unicycive Therapeutics, Inc. (the “Company”) issued a press release announcing the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on the path forward for Oxylanthanum Carbonate (OLC) and on the overall package requirements to file a New Drug Application.  A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

99.1 Press Release of Unicycive Therapeutics, Inc. dated October 23, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 23, 2023

 

  UNICYCIVE THERAPEUTICS, INC.
     
  By: /s/ Shalabh Gupta
  Shalabh Gupta
  Chief Executive Officer

 

 

2

 

 

 EX-99.1 2 ea187125ex99-1_unicycive.htm PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED OCTOBER 23, 2023

Exhibit 99.1

 

 

 

Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New
Drug Application for Oxylanthanum Carbonate (OLC)

 

- Pivotal clinical trial expected to initiate before year end -

 

LOS ALTOS, California, October 23, 2023 -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on the path forward for Oxylanthanum Carbonate (OLC) and on the overall package requirements to file a New Drug Application.

 

As reported in June, in the pre-NDA package shared with the FDA, the Agency requested clinical data in patients to proceed with the filing. Recently, during a Type C meeting with the FDA, the Company and the Agency reached an agreement on the overall data package requirements to file the NDA including clinical data, preclinical data, and CMC (chemistry, manufacturing, and controls). As a reminder, Unicycive intends to file the OLC NDA utilizing the 505(b)(2) regulatory pathway to reference the currently approved drug, Fosrenol®.

 

In the Type C meeting, plans were confirmed with the FDA for the pivotal clinical trial. The Agency requested 60 participants to be evaluated for 4 weeks on OLC once participants are titrated to clinically effective doses. The study is designed to evaluate tolerability and the event rate for discontinuation; therefore, there is no statistical analysis required to demonstrate efficacy. No other clinical study is required. We believe that results from this pivotal trial will enhance our safety data package from preclinical studies, and the efficacy data is referenced with Unicycive’s previously disclosed bioequivalence study.

 

“By working closely with the FDA, we have clear visibility into the requirements to file a full NDA data package for potential approval of OLC,” said, Shalabh Gupta, MD, Chief Executive Officer of Unicycive. “The alignment with the FDA includes all elements of our planned NDA package including clinical, preclinical, and CMC requirements. We expect to initiate the pivotal trial for OLC before the end of this year, with top line data expected in the second quarter of 2024. Once we complete the trial, we plan to finalize the NDA package and submit to the FDA.”

 

As of June 30, 2023, Unicycive’s cash position was reported as $18.8 million which is expected to last into the second half of 2024 including the ability to start and complete the pivotal clinical trial.

 

 

 

 

The planned clinical trial is expected to be an open-label, single-arm, multicenter, multidose study to evaluate the tolerability of clinically effective doses of OLC in participants with chronic kidney disease (CKD) on dialysis. As a reminder, all approved phosphate binders, including Fosrenol, are administered to patients on a dose titration schedule based on the control of serum phosphate. In Unicycive’s clinical trial, once participants have been titrated to a clinically effective dose with a serum phosphate range of ≤5.5 mg/dL, they will be treated for four weeks to evaluate serum phosphate levels.

 

About Hyperphosphatemia

 

Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). If left untreated, hyperphosphatemia leads to secondary hyperparathyroidism (SHPT), which then results in renal osteodystrophy (a condition similar to osteoporosis and associated with significant bone disease, fractures and bone pain); cardiovascular disease with associated hardening of arteries and atherosclerosis (due to deposition of excess calcium-phosphorus complexes in soft tissue). Importantly, hyperphosphatemia is independently associated with increased mortality for patients with chronic kidney disease on dialysis. Based on available clinical data to date, over 80% of patients show signs of cardiovascular calcification by the time they become dependent on dialysis.

 

Dialysis patients are already at an increased risk for cardiovascular disease (because of underlying diseases such as diabetes and hypertension), and hyperphosphatemia further exacerbates this. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

 

About Oxylanthanum Carbonate (OLC)

 

Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents globally. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden for patients in terms of number and size of pills per dose that are swallowed instead of chewed. Based on a survey conducted in 2022, Nephrologists stated that the greatest unmet need in the treatment of hyperphosphatemia with phosphate binders is a lower pill burden and better patient compliance.1 The global market opportunity for treating hyperphosphatemia is projected to be in excess of $2.5 billion in 2023, with the United States accounting for more than $1 billion of that total. Despite the availability of several FDA-cleared medications, 75 percent of U.S. dialysis patients fail to achieve the target phosphorus levels recommended by published medical guidelines.

 

Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. As part of the clinical development program, two clinical studies were conducted in over 100 healthy volunteers. The first study was a dose-ranging Phase I study to determine safety and tolerability. The second study was a randomized, open-label, two-way crossover bioequivalence study to establish pharmacodynamic bioequivalence between OLC and Fosrenol. Based on the topline results of the bioequivalence study, pharmacodynamic (PD) bioequivalence of OLC to Fosrenol was established.

 

Fosrenol® is a registered trademark of Shire International Licensing BV.

 

 

 

1Reason Research, LLC 2022 survey. Results here.

 

-2-

 

 

About Unicycive Therapeutics

 

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit Unicycive.com.

 

Forward-looking statements

 

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Investor Contact:

 

ir@unicycive.com

(650) 543-5470

 

SOURCE: Unicycive Therapeutics, Inc.

 

 

-3-

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 uncy-20231023.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 uncy-20231023_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 uncy-20231023_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 23, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 23, 2023
Entity File Number 001-40582
Entity Registrant Name Unicycive Therapeutics, Inc.
Entity Central Index Key 0001766140
Entity Tax Identification Number 81-3638692
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4300 El Camino Real
Entity Address, Address Line Two Suite 210
Entity Address, City or Town Los Alto
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94022
City Area Code (650)
Local Phone Number 351-4495
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol UNCY
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea187125-8k_unicycive_htm.xml IDEA: XBRL DOCUMENT 0001766140 2023-10-23 2023-10-23 iso4217:USD shares iso4217:USD shares 0001766140 false 8-K 2023-10-23 Unicycive Therapeutics, Inc. DE 001-40582 81-3638692 4300 El Camino Real Suite 210 Los Alto CA 94022 (650) 351-4495 Common Stock UNCY NASDAQ false false false false true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://unicycive.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea187125-8k_unicycive.htm uncy-20231023.xsd uncy-20231023_lab.xml uncy-20231023_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea187125-8k_unicycive.htm": { "nsprefix": "UNCY", "nsuri": "http://unicycive.com/20231023", "dts": { "inline": { "local": [ "ea187125-8k_unicycive.htm" ] }, "schema": { "local": [ "uncy-20231023.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "uncy-20231023_lab.xml" ] }, "presentationLink": { "local": [ "uncy-20231023_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://unicycive.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-23", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea187125-8k_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-23", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea187125-8k_unicycive.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://unicycive.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001013762-23-005659-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001013762-23-005659-xbrl.zip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end